EP3411411
1H-INDASÓL-3-KARBOXAMÍÐ-AFLEIÐUR OG SKYLD EFNASAMBÖND SEM D-ÞÁTTAR-HEMLAR Í MEÐFERÐ VIÐ SJÚKDÓMUM SEM EINKENNAST AF VIRKNI FRÁBRIGÐILEGS MAGNAKERFIS, SVO SEM T.D. ÓNÆMISFRÆÐILEGUM RÖSKUNUM
:
EP einkaleyfi: Endurútgefin þýðing EP einkaleyfis:
1.2.2017:
19.5.2021:
17748044.9
:
15.6.2021:
15.7.2021
:
31.1.2037:
31.1.2026:
28.2.2026
:
1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS
1.2.2017
19.5.2021
15.6.2021
15.7.2021
31.1.2026
:
Biocryst Pharmaceuticals, Inc.:
4505 Emperor Blvd., Durham, North Carolina 27703, US
:
KOTIAN, Pravin, L.:
Hoover, Alabama 35226, US
:
BABU, Yarlagadda, S.:
Birmingham AL 35244, US
:
ZHANG, Weihe:
Vestavia AL 35226, US
:
VOGETI, Lakshminarayana:
Lawrence, Kansas 66049, US
:
WU, Minwan:
Vestavia Hills AL 35226, US
:
CHINTAREDDY, Venkat, R.:
Vestavia Hills, Alabama 35216, US
:
RAMAN, Krishnan:
Birmingham AL 35244, US
:
Budde Schou A/S:
Dronningens Tværgade 30, DK
:
201662289653 P:
1.2.2016:
US
:
US2017015953:
1.2.2017
:
C07D 401/12, C07D 231/56, C07D 209/40, C07D 209/42, C07D 209/48, C07D 487/04, C07D 471/04, C07D 403/12, C07D 403/04, C07D 403/06, A61K 31/416, A61K 31/4439, A61K 31/404, A61K 31/4035, A61P 37/00, A61P 37/06, A61P 25/00, A61P 25/28, A61P 13/12, A61P 9/00, A61P 21/04, C07D 401/04, C07D 401/06, C07D 401/14, C07D 405/12, C07D 209/12, A61P 13/00
: 6
: 5.1.2022
: 31.1.2023
: Árnason Faktor ehf.
: 7
: 5.1.2023
: 31.1.2024
: Árnason Faktor ehf.
: 8
: 28.12.2023
: 31.1.2025
: Pintz & Partners LLC
: 9
: 19.12.2024
: 31.1.2026
: UAB METIDA